Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker CHRS · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | Trial of Atezolizumab and Bevacizumab With CHS-388 or Placebo in Patients With Hepatocellular Carci… NCT05359861 · Hepatocellular Carcinoma Casdozokitug, Atezolizumab | CHRS Coherus Oncology, Inc. | Phase 2 | Terminated | 30 | Jun 30, 2025 | Registry ↗ |
| Aug 12, 2026 | Study of CHS-114 in Participants With Advanced Solid Tumors NCT05635643 · Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma CHS-114, toripalimab | CHRS Coherus Oncology, Inc. | Phase 1 | Active, not recruiting | 87 | Sep 30, 2026 | Registry ↗ |
| Jul 30, 2026 | A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent… NCT06457503 · Nasopharyngeal Cancer Recurrent Toripalimab, Cisplatin | CHRS Coherus Oncology, Inc. | Phase 4 | Recruiting | 100 | Dec 2027 | Registry ↗ |
| Jul 15, 2026 | A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unres… NCT06679985 · Hepatocellular Carcinoma Casdozokitug, Toripalimab | CHRS Coherus Oncology, Inc. | Phase 2 | Active, not recruiting | 72 | Sep 2027 | Registry ↗ |
| Jul 15, 2026 | A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Particip… NCT06657144 · Metastatic Solid Tumor, Advanced Solid Tumor CHS-114, Toripalimab | CHRS Coherus Oncology, Inc. | Phase 1 | Recruiting | 154 | Jan 2028 | Registry ↗ |
| Jul 15, 2026 | Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors NCT04374877 · Advanced Solid Tumor, Clear Cell Renal Cell Carcinoma CHS-388, Pembrolizumab | CHRS Coherus Oncology, Inc. | Phase 1 | Completed | 145 | May 28, 2025 | Registry ↗ |
| May 8, 2025 | Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Cast… NCT05177770 · Metastatic Castration-resistant Prostate Cancer, Prostate C… SRF617, etrumadenant | CHRS Coherus Oncology, Inc. | Phase 2 | Terminated | 16 | Apr 5, 2023 | Registry ↗ |
| May 1, 2025 | Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advance… NCT05757492 · Advanced Solid Tumor, Non-Small Cell Lung Cancer CHS-006 (anti-TIGIT), toripalimab (anti-PD-1) | CHRS Coherus Oncology, Inc. | Phase 1 | Terminated | 22 | Jul 31, 2024 | Registry ↗ |
| Sep 19, 2024 | A Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors NCT06389526 · Advanced or Metastatic Solid Tumors CHS-1000, Toripalimab | CHRS Coherus Oncology, Inc. | Phase 1 | Not yet recruiting | 48 | May 30, 2028 | Registry ↗ |
| Jun 4, 2024 | Study of SRF617 in Patients With Advanced Solid Tumors NCT04336098 · Advanced Solid Tumor SRF617, Gemcitabine | CHRS Coherus Oncology, Inc. | Phase 1 | Completed | 85 | Aug 25, 2023 | Registry ↗ |
| Dec 23, 2020 | An Analysis to Estimate Febrile Neutropenia (FN) in Patients Receiving Udenyca NCT04662892 · Febrile Neutropenia, Non-myeloid Malignancy Pegfilgrastim-Cbqv | CHRS Coherus Oncology, Inc. | — | Unknown | 200 | Nov 1, 2022 | Registry ↗ |
| Apr 8, 2020 | Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis NCT02489227 · Plaque Psoriasis CHS-1420, Adalimumab | CHRS Coherus Oncology, Inc. | Phase 3 | Completed | 545 | May 6, 2016 | Registry ↗ |
| Jun 28, 2019 | Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO) NCT02134210 · Plaque Psoriasis Etanercept, CHS-0214 | CHRS Coherus Oncology, Inc. | Phase 3 | Completed | 521 | Jul 27, 2015 | Registry ↗ |
| Jun 26, 2019 | Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Rheumatoid Arthritis (RA) NCT02115750 · Rheumatoid Arthritis Etanercept, CHS-0214 | CHRS Coherus Oncology, Inc. | Phase 3 | Completed | 647 | Oct 2015 | Registry ↗ |
| Dec 27, 2018 | A Long Term Safety Extension Study (CHS-0214-05) NCT02486939 · Rheumatoid Arthritis, Plaque Psoriasis CHS-0214 | CHRS Coherus Oncology, Inc. | Phase 3 | Completed | 359 | Sep 2017 | Registry ↗ |
| Aug 1, 2016 | Study to Assess the Pharmacokinetic and Pharmacodynamic Bioequivalence of CHS-1701 With Neulasta NCT02650973 · Healthy CHS-1701, Pegfilgrastim | CHRS Coherus Oncology, Inc. | Phase 1 | Completed | 122 | Jun 2016 | Registry ↗ |
| Jan 7, 2016 | Assessing the Immunogenicity of 2 Subcutaneous Doses of CHS-1701 (Coherus Pegfilgrastim) With 2 Sub… NCT02418104 · Immunity, Humoral CHS-1701, Pegfilgrastim (Neulasta) | CHRS Coherus Oncology, Inc. | Phase 1 | Completed | 303 | Dec 2015 | Registry ↗ |
| Aug 13, 2015 | Comparison of the Pharmacokinetic and Pharmacodynamic Biosimilarity of CHS-1701 (Coherus Pegfilgras… NCT02385851 · Bioequivalence CHS-1701, Pegfilgrastim | CHRS Coherus Oncology, Inc. | Phase 1 | Completed | 116 | Jul 2015 | Registry ↗ |
18 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 8:20 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances